Biogen's CEO will depart and the biotech company is planning more deep cost cuts as it tries to move beyond a disastrous rollout for its Alzheimer’s disease drug Aduhelm https://t.co/QtCxJfB8Tf— Bloomberg (@business) May 3, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


